Fujinomiya, Japan

Hirofumi Endo


Average Co-Inventor Count = 3.6

ph-index = 3

Forward Citations = 45(Granted Patents)


Location History:

  • Fujinomiya, JA (1976)
  • Osaka, JA (1976)
  • Fujinomiya, JP (1983)

Company Filing History:


Years Active: 1976-1983

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Hirofumi Endo: Innovator in Prostaglandin Analogues

Introduction

Hirofumi Endo is a notable inventor based in Fujinomiya, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of prostaglandin analogues. With a total of 3 patents to his name, Endo's work has implications for therapeutic applications.

Latest Patents

Endo's latest patents include innovative compounds such as Trans-.DELTA..sup.2 -pge alkylsulphonyl amides and new prostaglandin analogues. These compounds are characterized by complex chemical structures that offer selective prostaglandin-like properties. His work on cyclodextrin clathrates further enhances the therapeutic utility of these compounds, making them valuable in medical applications.

Career Highlights

Hirofumi Endo is currently associated with Ono Pharmaceutical Co., Ltd., where he continues to advance his research. His expertise in prostaglandin compounds has positioned him as a key figure in pharmaceutical innovation. Endo's contributions are recognized within the scientific community for their potential impact on health and medicine.

Collaborations

Endo has collaborated with notable colleagues such as Masaki Hayashi and Seiji Kori. These partnerships have fostered a collaborative environment that enhances the research and development of new pharmaceutical products.

Conclusion

Hirofumi Endo's work in the field of prostaglandin analogues exemplifies the importance of innovation in pharmaceuticals. His patents and collaborations reflect a commitment to advancing medical science and improving therapeutic options.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…